Abstract

ObjectivesAntibacterial resistance (ABR) is a major global health security threat, with a disproportionate burden on lower-and middle-income countries (LMICs). It is not understood how ‘One Health’, where human health is co-dependent on animal health and the environment, might impact the burden of ABR in LMICs. Thailand's 2017 “National Strategic Plan on Antimicrobial Resistance” (NSP-AMR) aims to reduce AMR morbidity by 50% through 20% reductions in human and 30% in animal antibacterial use (ABU). There is a need to understand the implications of such a plan within a One Health perspective. MethodsA model of ABU, gut colonisation with extended-spectrum beta-lactamase (ESBL)-producing bacteria and transmission was calibrated using estimates of the prevalence of ESBL-producing bacteria in Thailand. This model was used to project the reduction in human ABR over 20 years (2020–2040) for each One Health driver, including individual transmission rates between humans, animals and the environment, and to estimate the long-term impact of the NSP-AMR intervention. ResultsThe model predicts that human ABU was the most important factor in reducing the colonisation of humans with resistant bacteria (maximum 65.7–99.7% reduction). The NSP-AMR is projected to reduce human colonisation by 6.0–18.8%, with more ambitious targets (30% reductions in human ABU) increasing this to 8.5–24.9%. ConclusionsOur model provides a simple framework to explain the mechanisms underpinning ABR, suggesting that future interventions targeting the simultaneous reduction of transmission and ABU would help to control ABR more effectively in Thailand.

Highlights

  • Antimicrobials have played an important role in the treatment and prevention of infectious diseases, have enabled food production to intensify and have greatly improved the lives of many millions of people

  • Over 20 years (2020–2040), the National Strategic Plan on Antimicrobial Resistance” (NSP-antimicrobial resistance (AMR)) in Thailand was estimated to reduce the number of humans colonised with resistant bacteria by 12.2% (95% credible interval: 6.0–18.8%, Table 2) from 2020 values by 2040

  • The NSP-AMR supplemented with an additional reduction in human-based antibacterial use (ABU) would reduce the burden of resistance (% colonised with resistant bacteria) within humans to a greater extent: to 16.7% (8.5–24.9%, Table 2) of 2020 values

Read more

Summary

Introduction

Antimicrobials have played an important role in the treatment and prevention of infectious diseases, have enabled food production to intensify and have greatly improved the lives of many millions of people. AMR, Antibacterial Resistance (ABR), occurs at the interface of a multifaceted One Health system; human health is thought to depend on the human population’s health-related behaviour, and on industrial, farming and veterinary practices as well as environmental conditions [4]. In the context of ABR, these diverse drivers can be separated into two components: “selection”, predomi­ nantly by antibacterial use (ABU) and “transmission” of resistant or­ ganisms between each connected compartment on a human-animalenvironment axis. The majority of global ABU is within animals raised for food (73%, [5,6]) and it is generally accepted that ABU in animals drives ABR [7], the magnitudes of these effects are poorly characterised and are likely to be antibacterial, resistance mechanism and organism specific. We do not know the full extent to which the listed factors of selection and transmission lead to the currently observed growing prevalence of ABR and increasing incidence of drug-resistant infections

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call